Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122003137?via=ihub
GLP1-RA decrease cardiovascular events [CE] but may worsen diabetic retinopathy [DR]. * Increase in DR was found in subcutaneous semaglutide >1 year and with decreases in A1c > 1.0%. *...
Conclusions: This meta-analysis may assist in decisions balancing the relative risk (of existing retinopathy) versus benefits (to existing CVD). There should be close collaboration with ophthalmology to grade the baseline degree of retinopathy when initiating and following patients.
Share
Semaglutide 2.4 mg for the management of obesity | DMSO
Obesity is a major global public health issue; the World Health Organisation estimated that in 2016 there were almost 2 billion adults worldwide with overweight and 650 million with obesity....
Conclusions: In NMA, semaglutide 2.4 mg demonstrated effective weight loss (≥ 5%) in the total population and all subpopulations of glucose tolerance versus active comparators. Semaglutide is an effective treatment that may address unmet need in the management of overweight and obesity.
Share
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials - Diabetology & Metabolic Syndrome
Source : https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-022-00970-2
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been highly recommended for glycemic control and weight reduction. However, evidence has accumulated that GLP-1 RAs treatment is related to an increase...
Conclusions: GLP-1 RAs therapy was not associated with an overall higher risk of arrhythmias, demonstrating an assuring cardiovascular safety profile. Further studies are required to determine whether the potential antiarrhythmic or arrhythmogenic effect of GLP-1 RAs is drug-specific and varies from doses or baseline BMI.
Share
Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
Source : https://www.sciencedirect.com/science/article/abs/pii/S2254887422001047?via=ihub
Available online 19 December 2022 This work aims to assess the effect of weekly subcutaneous semaglutide on biomarkers of metabolic-associated fatty liver disease (MAFLD), namely the hepatic steatosis index (HSI)...
/>
Conclusions: These results show that weekly subcutaneous semaglutide had a beneficial effect on liver steatosis that went beyond glucose control. Its effects were mainly related to weight loss, a decline in biomarkers, and improvements in insulin sensitivity. For many patients, early detection is essential for improving MAFLD outcomes and may...
Share
Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36542260/
Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands...
Conclusions: Individuals with T2D treated with OW semaglutide experienced significant and clinically relevant improvements in glycaemic control and BW from baseline. These results from a diverse real-world population in the Netherlands support the use of OW semaglutide in treating adults with T2D in routine clinical practice.
Share